Liver function may change how inavolisib works

NCT ID NCT07144111

Recruiting now Knowledge-focused Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 6 times

Summary

This early-phase study looks at how a single dose of the drug inavolisib behaves in people with moderate or severe liver impairment compared to healthy volunteers. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand if liver problems change how the drug is processed, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inavolisib
What this could lead to: If successful, this study could help doctors understand how to dose inavolisib safely for patients with liver problems.
What could go wrong: This is a very early, small study (32 people) focused on drug levels, not on treating a disease. Results may not apply to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Orange County Research Center
RECRUITING

Lake Forest, California, 92630, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
Pinnacle Clinical Research - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
The Texas Liver Institute, Inc.
RECRUITING

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.